Imipenem/Cilastatin Aptapharma

Imipenem, the active ingredient in Imipenem/Cilastatin Aptapharma, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, skin and soft tissue infections, nosocomial pneumonia, and septicemia in hospitalized patients.

GNH USA supplies Imipenem/Cilastatin Aptapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imipenem/Cilastatin is a broad‑spectrum carbapenem used for serious bacterial infections that require intravenous therapy.

- Complicated intra‑abdominal infections: achieves rapid bacterial eradication and clinical cure. - Complicated urinary tract infections: provides bactericidal activity against resistant uropathogens. - Skin and soft tissue infections: resolves infection and limits tissue damage. - Nosocomial pneumonia: penetrates lung tissue to treat hospital‑acquired respiratory infections. - Septicemia: delivers systemic antibacterial effect to control bloodstream infection.

Adverse reactions may occur with any intravenous antibiotic and should be monitored.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Elevated liver enzymes: transient increase in ALT/AST. - Injection site pain: local discomfort during infusion. - Headache: mild, transient.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Seizures: especially in patients with renal impairment or high doses. - Clostridioides difficile colitis: severe diarrhea due to gut flora disruption. - Thrombocytopenia: reduced platelet count. - Renal dysfunction: acute kidney injury in susceptible individuals. - Stevens‑Johnson syndrome: rare severe skin reaction.

Use Imipenem/Cilastatin only under medical supervision and consider patient‑specific risk factors.

- Renal impairment: adjust dose or monitor renal function closely. - History of seizures: evaluate risk before administration. - Hypersensitivity: avoid if known allergy to carbapenems or β‑lactams. - Concomitant valproic acid: monitor for reduced seizure control. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Drug interactions can affect efficacy or safety and should be reviewed before therapy.

Major Interactions (Avoid): - Valproic acid: may reduce antiepileptic effect of valproate. - Probenecid: can increase plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate electrolyte disturbances. - Aminoglycosides: increased risk of nephrotoxicity. - Warfarin: monitor INR for potential anticoagulant effect changes. - Rifampin: may lower imipenem levels. - NSAIDs: monitor renal function when combined.